GSK 650394 100 mg | 98.93%
TargetMol
GSK 650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor.
More Information Supplier PageGSK 650394
Search Results
GSK 650394 2 mg | 98.93%
TargetMol
GSK 650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor.
More Information Supplier PageGSK 650394
GSK2656157 2 mg | 99.89%
TargetMol
GSK2656157 is a highly specific and ATP-competitive PERK inhibitor (IC50: 0.9 nM) in a cell-free assay. The selectivty is 500-fold higher against a panel of 300 kinases.
More Information Supplier PageGSK2656157
GSK2656157 25 mg | 99.89%
TargetMol
GSK2656157 is a highly specific and ATP-competitive PERK inhibitor (IC50: 0.9 nM) in a cell-free assay. The selectivty is 500-fold higher against a panel of 300 kinases.
More Information Supplier PageGSK2656157
TGX-221 2 mg | 98.98%
TargetMol
TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.
More Information Supplier PageTGX-221
GW2580 200 mg | 99.48%
TargetMol
GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
More Information Supplier PageGW2580
GW2580 100 mg | 99.48%
TargetMol
GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
More Information Supplier PageGW2580
CEP-37440 25 mg | 99.01%
TargetMol
CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
More Information Supplier PageCEP-37440
CEP-37440 1 mg | 99.01%
TargetMol
CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
More Information Supplier PageCEP-37440
GSK2656157 200 mg | 99.89%
TargetMol
GSK2656157 is a highly specific and ATP-competitive PERK inhibitor (IC50: 0.9 nM) in a cell-free assay. The selectivty is 500-fold higher against a panel of 300 kinases.
More Information Supplier PageGSK2656157
